Encompass Health Q2 revenue rises, adjusted EPS beats estimates
EHC•Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the healthcare facilities & services peer group is "buy"
- Wall Street's median 12-month price target for Encompass Health Corp is $140.00, about 26.7% above its August 4 closing price of $110.50
- The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 16 three months ago
Quarterly results
- U.S. rehab hospital operator's Q2 revenue rose 9.6% yr/yr
- Adjusted EPS for Q2 beat analyst expectations
- Company raised full-year guidance and expanded stock buyback authorization to $1 bln
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q2 Operating Revenue | $1.6 bln | ||
| Q2 Adjusted EPS | Beat | $1.55 | $1.48 (13 Analysts) |
Outlook and operating drivers
-
Company raises 2026 net operating revenue guidance to $6.41 bln-$6.49 bln
-
Encompass Health now sees 2026 adjusted EBITDA of $1.365 bln-$1.395 bln
